Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Aktis Oncology, Inc. Common stock(AKTS)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for AKTS
09/25/2026: AKTS (1-star) is currently NOT-A-BUY. Pass it for now.
Aktis Oncology is a clinical-stage biotechnology company focused on developing targeted radiopharmaceuticals for solid tumors using a proprietary miniprotein platform. Its strength lies in its specialized technology and a pipeline addressing unmet cancer needs, bolstered by a strong cash position following its January 2026 IPO. The investment story centers on the upcoming data readouts for lead candidates AKY-1189 and AKY-2519. However, the company faces significant risks as a pre-commercial firm, including high cash burn, intense competition from pharmaceutical giants, and the inherent uncertainty of clinical trials. This stock is best suited for high-risk growth investors who should monitor clinical progress and partnership announcements closely.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company offers exposure to high-growth potential in targeted oncology therapies. |
| Momentum investor | Mixed fit | Momentum is conditional on positive clinical trial data and regulatory news flow. |
| Value investor | Weak fit | The company lacks current profitability and traditional valuation metrics. |
| Dividend investor | Weak fit | No dividend is paid as the company reinvests all capital into R&D. |
| Low-risk investor | Weak fit | Clinical-stage biotech involves high volatility and binary trial outcome risks. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical-stage stocks frequently experience sharp swings based on trial results. |
| Valuation risk | Medium / high | Valuation is speculative, depending entirely on future pipeline success. |
| Competition risk | High | Large-cap firms like Novartis aggressively compete in the radiopharmaceutical space. |
| Business quality | Medium | The company relies heavily on the success of its proprietary miniprotein platform. |
| Dividend income | Low / none | The company does not provide income for yield-focused investors. |
| Execution risk | High | Success depends on meeting rigorous clinical trial and regulatory standards. |
Price Behavior
Rolling Over
The price momentum is slowing down and beginning to turn downward.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit -8.12% | Avg. Invested days 34 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/25/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.08B USD | Price to earnings Ratio - | 1Y Target Price 35.39 |
Price to earnings Ratio - | 1Y Target Price 35.39 | ||
Volume (30-day avg) 433.1K shares | Beta - | 52 Weeks Range 14.72 - 34.19 | Updated Date 09/26/2026 |
52 Weeks Range 14.72 - 34.19 | Updated Date 09/26/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.32 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Radiopharmaceutical Collaborations | Milestone payments and research funding from pharmaceutical partnership agreements. | Revenue comes from partnerships rather than selling commercial drugs, making it highly dependent on pipeline progress. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 589.90M | Price to Sales(TTM) 107.42 |
Enterprise Value 589.90M | Price to Sales(TTM) 107.42 | ||
Enterprise Value to Revenue 58.64 | Enterprise Value to EBITDA - | Shares Outstanding 53.75M | Shares Floating 28.59M |
Shares Outstanding 53.75M | Shares Floating 28.59M | ||
Percent Insiders 14.05 | Percent Institutions 72.9 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Aktis Oncology, Inc. Common stock
Exchange NASDAQ | Headquarters Boston, MA, United States | ||
IPO Launch date 2026-01-09 | President, CEO & Director Dr. Matthew Roden Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 79 | Website https://www.aktisoncology.com |
Full time employees 79 | Website https://www.aktisoncology.com | ||
Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and [225Ac]Ac-AKY-2519 to deliver 225Ac to B7-H3 (CD276) expressing tumors, including prostate, lung and other solid tumors. It has license and collaboration agreements with Protein Innovation, Inc., TRIUMF Innovations, Inc., and Eli Lilly. The company was formerly known as HotKnot Therapeutics, Inc. and changed its name to Aktis Oncology, Inc. in April 2020. Aktis Oncology, Inc. was incorporated in 2020 and is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.